Key result
Randomization of 42,448 hypertensive patients to chlorthalidone, amlodipine, lisinopril, or doxazosin yielded well-balanced baseline characteristics with no important differences between groups.
Why the study?
Do newer antihypertensive agents (amlodipine, lisinopril, doxazosin) reduce fatal coronary heart disease or nonfatal myocardial infarction compared to chlorthalidone in hypertensive patients aged >=55 years with at least 1 other CVD risk factor?
RCT (n=42,448)
Double-blind
Randomized
Yes
Do newer antihypertensive agents (amlodipine, lisinopril, doxazosin) reduce fatal coronary heart disease or nonfatal myocardial infarction compared to chlorthalidone in hypertensive patients aged >=55 years with at least 1 other CVD risk factor?
The ALLHAT trial successfully randomized a large, ethnically diverse cohort of high-risk hypertensive patients to compare newer antihypertensive agents against a traditional diuretic.
Answers are grounded in this paper and cite their sources.
Baseline balance confirms valid randomization; extends reliability of ALLHAT outcome comparisons in high-risk hypertension.
-Diuretics and ss-blockers have been shown to reduce the risk of cardiovascular morbidity and mortality in people with hypertension in long-term clinical trials. No study has compared newer more costly antihypertensive agents (calcium antagonists, ACE inhibitors, and alpha-adrenergic blockers) with diuretics for reducing the incidence of cardiovascular disease in an ethnically diverse group of middle-aged and elderly hypertensive patients. The study is a randomized, double-blind, active-controlled clinical trial designed to determine whether the incidence of the primary outcome, fatal coronary heart disease or nonfatal myocardial infarction, differs between treatment initiation with a diuretic versus each of 3 other antihypertensive drugs. Men and women aged >/=55 years with at least 1 other cardiovascular disease risk factor were randomly assigned to chlorthalidone (12.5 to 25 mg/d), amlodipine (2.5 to 10 mg/d), lisinopril (10 to 40 mg/d), or doxazosin (2 to 8 mg/d) for planned follow-up of 4 to 8 years. This report describes the baseline characteristics of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants. A total of 42 448 participants were randomized from 625 sites in the United States, Canada, Puerto Rico, and the US Virgin Islands. The mean age was 67 years, with 35% aged >/=70 years. Among those randomized, 36% were black, 19% were Hispanic, and 47% were women. The sample includes a high proportion of people with diabetes (36%), patients with existing cardiovascular disease (47%), and smokers (22%). There were no important differences between the randomized treatment groups at baseline. ALLHAT will add greatly to our understanding of the management of hypertension by providing an answer to the following question: are newer antihypertensive agents similar, superior, or inferior to traditional treatment with diuretics?
No takes yet. Share an insight, caveat, or question.
Grimm et al. (2001) conducted an RCT in Hypertension (n=42,448). Amlodipine, lisinopril, or doxazosin vs. Chlorthalidone (12.5 to 25 mg/d) was evaluated on Fatal coronary heart disease or nonfatal myocardial infarction. Randomization of 42,448 hypertensive patients to chlorthalidone, amlodipine, lisinopril, or doxazosin yielded well-balanced baseline characteristics with no important differences between groups.
Synapse has enriched 10 related papers. Consider them for comparative context: